Abstracts Archive - Page 10 of 2616 - ACR Meeting Abstracts

Abstract Number: 138 • 2026 Pediatric Rheumatology Symposium
Demographic, Clinical and Major Histocompatibility Complex (MHC) variation associated with uveitis development in children with juvenile idiopathic arthritis
Sheila Angeles-Han¹, Susan Thompson², Hermine Brunner³, Hannah Ainsworth⁴, Mekibib Altaye⁵, Minal Aundhia³, John Bohnsack⁶, Margaret Chang⁷, ashley cooper⁸, Stefanie Davidson⁹, Alexandra Duell³, Timothy Howard¹⁰, Melissa Lerman¹¹, Mindy Lo¹², Ilaria Maccora¹³, Miranda Marion⁴, Bharti Nihalani-Gangwani¹⁴, Sampath Prahalad¹⁵, Cristina Reina¹⁶, Megan Quinlan-Waters¹⁶, Grant Schulert³, Gabriele Simonini¹⁷, Colin Speer¹⁸, erin stahl⁸, marc Sudman³, Virginia Miraldi Utz³, Michael Wagner¹⁶ and Carl Langefeld¹⁹ for the CARRA Registry Investigators, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Wake Forest University School of Medicine, Winston-Salem, NC, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶University of Utah, Salt Lake City, UT, ⁷Boston Children's Hospital, Newton, MA, ⁸Children's Mercy Kansas City, Kansas City, MO, ⁹University of Pennsylvania/CHOP, Philadelphia, PA, ¹⁰Wake Forest University School of Medicine, Quakertown, PA, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Boston Children's Hospital, Boston, MA, ¹³Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Firenze, Italy, ¹⁴Boston Children's Hospital, ¹⁵Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁶Cincinnati Children's Hospital Medical Center, ¹⁷Meyer Children's Hospital, Florence, Italy, ¹⁸Wake Forest University School of Medicine, ¹⁹Wake Forest University School of Medicine, Winston Salem, NC
Background/Purpose: Chronic anterior uveitis (CAU) occurs in 10-20% of JIA patients, yet the factors driving risk for JIA-associated uveitis (JIA-U) are not established. The HLA…
Abstract Number: 142 • 2026 Pediatric Rheumatology Symposium
Improving Recognition and Management of Glucocorticoid-Induced Adrenal Insufficiency in Pediatric Rheumatology Patients
Emily Schildt¹, Hayley Lynch², Natalie Rosenwasser², Susan Shenoi³, Lori Rutman⁴ and Meenal Gupta⁵, ¹Seattle Children's Hospital, Kenmore, WA, ²Seattle Children's Hospital, Seattle, WA, ³Seattle Children's Hospital and Research Center, Mercer Island, WA, ⁴UW - Seattle Children’s, ⁵University of Washington, Seattle Children's Hospital
Background/Purpose: Patients with systemic autoimmune diseases like childhood-onset systemic lupus erythematosus (cSLE) and juvenile dermatomyositis (JDM) typically receive oral glucocorticoids at the onset of their…
Abstract Number: 022 • 2026 Pediatric Rheumatology Symposium
Mental Health concerns in Patients with Juvenile Idiopathic Arthritis and Their Caregivers: A Systematic Review
Hanul (Erica) Park¹, Aya Zebian², Alyssa Pennigton², Emaan Awan², Matthew Sholdice³, Andrea Knight⁴ and Roberta A Berard⁵, ¹London Children's Hospital, ON, Canada, ²Western University, ON, Canada, ³McMaster University, London, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵London Health Sciences Centre, London, ON, Canada
Background/Purpose: The COVID-19 pandemic has amplified mental health (MH) challenges among youth, with one in five children reporting their MH to be “fair” or “poor”.…
Abstract Number: 122 • 2026 Pediatric Rheumatology Symposium
Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
Chelsea Reynolds¹, Natasha Ruth² and Joyce Chang³, ¹MUSC, ²Medical University South Carolina, Charleston, SC, ³Boston Children's Hospital, Newton, MA
Background/Purpose: Recent research suggests that multidimensional area-level indicators, including the Social Vulnerability Index (SVI), Area Deprivation Index (ADI) and Childhood Opportunity Index (COI), associate with…
Abstract Number: 126 • 2026 Pediatric Rheumatology Symposium
Unmet Social Needs in Pediatric Rheumatic Disease: A Study of Disparities
Hana Moosa¹, Kristina Ciaglia², Yuhan Ma³ and Elizabeth Sloan¹, ¹UT Southwestern, TX, ²UT Southwestern, Dallas, TX, ³Texas Scottish Rite for Children, TX
Background/Purpose: Children with rheumatic diseases often face social determinants of health (SDoH) that affect access and outcomes, yet data in pediatric rheumatology remain limited. We…
Abstract Number: 073 • 2026 Pediatric Rheumatology Symposium
Interleukin-6 and Interleukin-12 Stimulation Increases Fibroblast Migration in Localized Scleroderma and Healthy Control Primary Fibroblasts
Angelina Dressel¹, Daniel Barnett² and Kathryn Torok³, ¹UPMC Children's Hospital of Pittsburgh, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is an inflammation-driven fibrotic disease, presenting clinically as linear bands, patches, or regions of skin and underlying connective tissues with initial…
Abstract Number: 113 • 2026 Pediatric Rheumatology Symposium
Risk Assessment for Pediatric Rheumatic Diseases in Children with a History of Kawasaki Disease: A Long-Term Retrospective Comparative Big Data Cohort Study
Rim Kasem Ali Sliman¹ and Mohamad Hamad Saied², ¹² Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa ^3109601, Israel., Hefa, Israel, ²Carmel medical centre, Haifa, Israel
Background/Purpose: Kawasaki disease (KD) is an acute systemic vasculitis predominantly affecting children under 5 years old. Although primarily known for its cardiac complications, the long-term…
Abstract Number: LB20 • ACR Convergence 2025
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Désirée van der Heijde¹, Philip Mease², Carle Paul³, Frank Behrens⁴, Laure Gossec⁵, Yuko Kaneko⁶, Lihi Eder⁷, Laura Coates⁸, Andrew Pink⁹, Weiguo Wan¹⁰, Enrique Soriano¹¹, Piotr Leszczyński¹², Jose Scher¹³, Atul Deodhar¹⁴, Chahin Pachai¹⁵, Janice Li¹⁶, Xue Fan¹⁶, Sahar Rabbat¹⁶, Caroline Sardinas¹⁷, Michael Plewinski¹⁸, John Vaile¹⁹ and Joseph Merola²⁰, ¹Leiden University Medical Center, Meerssen, Netherlands, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, Washington, ³Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, France, ⁴Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁵Sorbonne Université, AP-HP & EULAR, Paris, France, ⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁷University of Toronto, Toronto, Ontario, Canada, ⁸University of Oxford, Oxford, United Kingdom, ⁹St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom, ¹⁰Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ¹¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹²Department of Internal Medicine and Metabolic Disorders, Poznań University of Medical Sciences, Poznań, Poland, ¹³New York University School of Medicine, New York, New York, ¹⁴Oregon Health & Science University, Portland, Oregon, ¹⁵Bristol Myers Squibb, Princeton, New Jersey, ¹⁶Bristol Myers Squibb, Princeton, ¹⁷Bristol Myers Squibb, garwood, New Jersey, ¹⁸Bristol Myers Squibb, Green Brook Township, New Jersey, ¹⁹Bristol Myers Squibb, Warren, New Jersey, ²⁰UT Southwestern Medical Center, Dallas, Texas
Background/Purpose: Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor being investigated in active PsA in the global, randomized, double-blind, placebo (PBO)-controlled, phase 3…
Abstract Number: LB24 • ACR Convergence 2025
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)
Thomas Grader-Beck¹, Xavier Mariette², Stephanie Finzel³, Elena Schiopu⁴, Athena Papas⁵, Valerie Devauchelle-Pensec⁶, Thomas Dörner⁷, Monika Sopala⁸, Xiaofeng Zeng⁹, Ghaith Noaiseh¹⁰, Tsutomu Takeuchi¹¹, Uma Kumar¹², Josef Hermann¹³, Hiroki Ozawa¹⁴, Robert Fox¹⁵, Susan Zong¹⁶, Deepak Narayanswamy¹⁷, XIAOMEI LI¹⁸, Wen-Lin Luo¹⁹, Janice Woznicki²⁰, Laurie DeBonnett²¹, Xuan Zhu²⁰, Linchen He²⁰, Franziska Matzkies²², Angelika Jahreis²², Brian Porter²³, Sara McCoy²⁴, Simon Bowman²⁵ and Wolfgang Hueber²², ¹Johns Hopkins, Reisterstown, Maryland, ²Universit Paris-Saclay, Le Kremlin-Bictre, France, ³University Medical Center Freiburg, Freiburg, Germany, ⁴Medical College of Georgia at Augusta University, Martinez, Georgia, ⁵Tufts School of Dental Medicine, Boston, Massachusetts, ⁶Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U1227), LabEx IGO, Brest, France, ⁷Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum,, Berlin, Germany, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ¹⁰University of Kansas Medical Center, Kansas City, Kansas, ¹¹Division of Rheumatology and Clinical Immunology, Keio University,, Tokyo, Japan, ¹²Department of Rheumatology, All India Institute of Medical Sciences,, New Delhi, India, ¹³Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz,, Graz, Austria, ¹⁴Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ¹⁵Division of Rheumatology, Scripps Memorial Hospital and Research Foundation-Ximed, La Jolla,, San Diego, California, ¹⁶Novartis Pharmaceuticals Corporation, Bridgewater Township, New Jersey, ¹⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹⁸First Affiliated Hospital of China University of Science and Technology, Hefei, China, ¹⁹Novartis Pharmaceuticals Corporation, Franklin Township, New Jersey, ²⁰Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, ²¹Novartis Pharmaceuticals Corporation, Mt Olive, New Jersey, ²²Novartis Pharma AG, Basel, Switzerland, ²³Novartis Pharmaceuticals, East Hanover, New Jersey, ²⁴University of Wisconsin, Middleton, Wisconsin, ²⁵University Hospitals Birmingham, Birmingham, United Kingdom

Background/Purpose: Sjögren's disease (SjD) is a systemic, heterogeneous, autoimmune disease with substantial disease burden, high unmet need, and no approved systemic treatments. B cell hyperactivity…
Abstract Number: LB21 • ACR Convergence 2025
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Flore Castellan¹, Griffen Mustion², Mei-Kay Wong¹, Kimberly Johansson², Scott Goldberg¹, Yazan Madanat³, Namrata Chandhok⁴, Abhay Singh⁵, David Sallman⁶, Jane Churpek⁷, Curtis Lachowiez⁸, Jennifer Yannucci⁹, Luke Fletcher¹⁰, Matthew Schwede¹¹, Amber Afzal², Yael Kusne¹², Alejandro Marinos¹³, Alexander Coltoff¹⁴, Rickey Myhand¹⁵, Kiran Vij², Rosalyn Marar¹⁶, Hannah Mitchell², Maria Stoentcheva², Giulia Petrone², Kyra Ddungu², Hannah Hartman², Ryan Monahan², Karen Vandervort², Jie Liu², John Cole², Tibor Kovacsovics¹⁷, Hetty Carraway¹⁸, Tian Zhang¹⁹, Stephen Chung³, Geoffrey Uy², Eytan Stein²⁰, Devendra Hiwase²¹, Matthew Walter², Mrinal Patnaik¹⁶, Kelly Bolton²² and David Beck¹, ¹New York University School of Medicine, New York, New York, ²Washington University School of Medicine, Saint Louis, Missouri, ³UT Southwestern Medical Center, Dallas, Texas, ⁴University Miami Miller School of Medicine, Miami, Florida, ⁵Cleveland Clinic, Cleveland, Ohio, ⁶Moffitt Cancer Center, Tampa, Florida, ⁷University of Wisconsin School of Medicine, Madison, Wisconsin, ⁸Oregon Health & Science University, Portland, Oregon, ⁹Low Country Cancer Care, Savannah, Georgia, ¹⁰Willamette Valley Cancer Institute and Research Center, EUgene, Oregon, ¹¹Swedish Health Services, Seattle, Washington, ¹²Mayo Clinic, Phoenix, Arizona, ¹³UTSouthwestern Medical Center, Dallas, Texas, ¹⁴Medical University of South Carolina, Charleston, South Carolina, ¹⁵CovenantOntology & Hematology, Frankfort, Kentucky, ¹⁶Mayo Clinic, Rochester, Minnesota, ¹⁷City of Hope, Goodyear, Arizona, ¹⁸Case Western Reserve University, Cleveland, Ohio, ¹⁹Stanford Medicine, Stanford, California, ²⁰Memorial Sloan Kettering Cancer Center, New York, New York, ²¹Adelaide Medical School, Adelaide, South Australia, Australia, ²²Washington University School of Medicine, Saint Louis, Minnesota
Background/Purpose: Recently, somatic mutations in hematopoietic stem and progenitor cells (HSPCs) have been proposed as a novel mechanism driving systemic inflammation. UBA1 somatic variants in…
Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: LB17 • ACR Convergence 2025
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Sitian Zang¹, Ranran Yao¹, Yan Wang¹, Danxue Zhu¹, Jing He¹ and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking Univeristy People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) features heterogeneous clinical manifestations. The identification of biomarkers that facilitate initial disease recognition is a cornerstone of optimized clinical management.…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].